Rheumatology Practice Management February 2017 Vol 5 No 1
“Strict or bureaucratic oversight programs for drug or medical treatments have delayed access to necessary care, wasted limited health care resources and antagonized patients and physicians alike.
Consider the opportunity to “code” certain aspects of a patient’s medical history, or a socioeconomic situation as a static field that reduces the need to individually select that code with each encounter
ACR Applauds 21st Century Cures Act, But Urges Congress to Dedicate Funds for Arthritis Research Program
“Despite epidemic- level rates of arthritis in our Armed Forces and the burgeoning cost of this disease to the U.S. military, there is currently no dedicated Department of Defense budget for medical research on arthritis.”
The following clinical trials represent a selection of key studies that are currently recruiting patients with psoriatic arthritis for inclusion in investigations of new therapies and new regimens of existing treatments for individuals with the disease.
Institute for Clinical and Economic Review Releases Draft Report on Therapies for Rheumatoid Arthritis
On March 24, 2017, this report will be the topic of a free, public meeting held by the New England Comparative Effectiveness Public Advisory Council, a nationally recognized community forum and core program of ICER, in Boston, MA. During this meeting, recommendations that can be translated to policy and practice in the field of rheumatology will be deliberated by an expert policy roundtable, and the New England Comparative Effectiveness Public Advisory Council will vote on important questions brought up in the Draft Evidence Report.
The National Organization of Rheumatology Managers (NORM) would like to acknowledge the efforts of organizations such as the Coalition of State Rheumatology Organizations, the National Infusion Center Association, the Community Oncology Alliance, and the American College of Rheumatology for their unwavering resistance to the Medicare Part B Demonstration Project.
“The ACR supports the FDA’s recommendation of distinct suffixes for both biosimilars and reference biologics, so as to prevent prescribers from perceiving that drugs with suffixes are less safe or effective.
MACRA provides $20 million each year for 5 years to fund training and education for Medicare physicians in individual- or small group practices of ≤15 physicians, and those working in underserved areas.
Results 1 - 8 of 8